The lentiviral vector manufacturing market is driven mainly by the growing demand for lentiviral vectors in vaccine development, increasing adoption for treating genetic and acquired disorders ...

Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities. The companies entered a definitive agreement in May ...

--Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT ® VirusGEN ® GMP product line. "Gene and cell therapy manufacturers have faced many challenges ...

Merck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive agreement to acquire Mirus Bio in a $600m (€500m) deal.

Fred Hutch's Cooperative Center of Excellence in Hematology Vector Production core assists investigators with the design, construction, and/or production of viral vectors (gammaretrovirus, lentivirus, ...

The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.

Its expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus.

The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.

These production/concentration methods result in high-titer vector preparations that show reduced toxicity compared with lentiviral vectors produced using standard protocols involving ...

Mirus Bio’s transfection reagents strengthen MilliporeSigma’s upstream portfolio Acquisition will advance company’s ambition to provide a fully integrated and comprehensive solution for viral vector ...